[go: up one dir, main page]

CR9219A - Derivados de triazol sustituidos como antagonistas de oxitocina - Google Patents

Derivados de triazol sustituidos como antagonistas de oxitocina

Info

Publication number
CR9219A
CR9219A CR9219A CR9219A CR9219A CR 9219 A CR9219 A CR 9219A CR 9219 A CR9219 A CR 9219A CR 9219 A CR9219 A CR 9219A CR 9219 A CR9219 A CR 9219A
Authority
CR
Costa Rica
Prior art keywords
oxitocine
antagonists
derivatives replaced
triazol derivatives
triazol
Prior art date
Application number
CR9219A
Other languages
English (en)
Inventor
Daniel Brown Alan
Anthony Calabrese Andrew
Ellis David
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CR9219A publication Critical patent/CR9219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a triazoles sustituidos de formula (1), a usos, a procedimientos para su preparacion y a composiciones que contienen dichos compuestos. Estos inhibidores tienen utilidad en diversas areas terapeuticas incluyendo disfuncion sexual.
CR9219A 2005-01-20 2007-07-02 Derivados de triazol sustituidos como antagonistas de oxitocina CR9219A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0501190.3A GB0501190D0 (en) 2005-01-20 2005-01-20 Novel pharmaceuticals

Publications (1)

Publication Number Publication Date
CR9219A true CR9219A (es) 2007-07-24

Family

ID=34259404

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9219A CR9219A (es) 2005-01-20 2007-07-02 Derivados de triazol sustituidos como antagonistas de oxitocina

Country Status (31)

Country Link
US (5) US7557131B2 (es)
EP (1) EP1841758B1 (es)
JP (1) JP4124805B1 (es)
KR (1) KR100936854B1 (es)
CN (1) CN101107243B (es)
AP (1) AP2007004047A0 (es)
AR (1) AR055303A1 (es)
AT (1) ATE449091T1 (es)
AU (1) AU2006207300B2 (es)
BR (1) BRPI0606463A2 (es)
CA (1) CA2595569C (es)
CR (1) CR9219A (es)
DE (1) DE602006010508D1 (es)
DK (1) DK1841758T3 (es)
DO (1) DOP2006000014A (es)
EA (1) EA200701328A1 (es)
ES (1) ES2334517T3 (es)
GB (1) GB0501190D0 (es)
GT (1) GT200600024A (es)
IL (1) IL184148A (es)
MA (1) MA29160B1 (es)
MX (1) MX2007008757A (es)
NL (1) NL1030961C2 (es)
NO (1) NO338420B1 (es)
PA (1) PA8660401A1 (es)
PE (1) PE20060875A1 (es)
TN (1) TNSN07275A1 (es)
TW (1) TW200637847A (es)
UY (1) UY29339A1 (es)
WO (1) WO2006077496A1 (es)
ZA (1) ZA200705718B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06284516A (ja) * 1993-03-31 1994-10-07 Mitsubishi Electric Corp 電気車制御装置
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
JP2008545760A (ja) * 2005-06-09 2008-12-18 メルク フロスト カナダ リミテツド ステアロイル−コエンザイムａデルタ−９デサチュラーゼのインヒビターとしてのアザシクロヘキサン誘導体
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
CA2654792A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2032570A4 (en) * 2006-06-13 2010-10-27 Merck Frosst Canada Ltd AZACYCLOPENTATE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
JP2010527915A (ja) * 2007-04-26 2010-08-19 アバロン ファーマシューティカルズ，インコーポレイテッド 多重環化合物及びその用途
WO2009095163A2 (en) * 2008-01-31 2009-08-06 Sanofi-Aventis Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals
WO2009095162A1 (en) * 2008-01-31 2009-08-06 Sanofi-Aventis Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
MY171483A (en) * 2012-07-16 2019-10-15 Fibrogen Inc Process for making isoquinoline compounds
WO2016014975A2 (en) 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JP6990702B2 (ja) 2016-11-18 2022-01-13 インテグレーティブ リサーチ ラボラトリーズ スウェーデン アーベー 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体
EP3560918A4 (en) * 2016-12-21 2020-05-20 Jiangsu Hengrui Medicine Co., Ltd. TRIAZOLE DERIVATIVE FROM THE CONDENSED CYCLE AZACYCLOBUTYL GROUP, PREPARATION METHOD THEREOF AND USE IN MEDICINE
US20210040073A1 (en) * 2016-12-28 2021-02-11 Jiangsu Hengrui Medicine Co., Ltd. Azabicyclo-substituted triazole derivative, preparation method thereof, and application of same in medicine
WO2019242646A1 (zh) * 2018-06-20 2019-12-26 江苏恒瑞医药股份有限公司 催产素受体抑制剂的晶型及其制备方法
WO2019242642A1 (zh) * 2018-06-20 2019-12-26 江苏恒瑞医药股份有限公司 一种otr抑制剂的可药用盐、晶型及制备方法
CN111902406B (zh) * 2018-06-27 2022-11-18 江苏恒瑞医药股份有限公司 氮杂双环基取代的三唑类衍生物的可药用盐、晶型及制备方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法
CN113582818B (zh) * 2021-08-30 2023-08-01 上海日异生物科技有限公司 一种3-卤-2-烷基苯酚的合成方法
EP4444305A2 (en) * 2022-02-16 2024-10-16 Duke Street Bio Limited Pharmaceutical compound
CN114805161B (zh) * 2022-06-14 2023-08-25 南通华祥医药科技有限公司 一种3-氟丫丁啶盐酸盐的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554276A (en) 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US5053411A (en) 1989-04-20 1991-10-01 Anaquest, Inc. N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1997036897A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891339A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507956A (ja) 1996-04-03 2000-06-27 メルク エンド カンパニー インコーポレーテッド ファルネシル−タンパク質トランスフェラーゼ阻害剤
CA2276081A1 (en) 1996-12-30 1998-07-09 Lekhanh O. Tran Inhibitors of farnesyl-protein transferase
SK8782000A3 (en) 1997-12-16 2002-03-05 Pfizer Prod Inc Combination, composition and kits effective for the treatment of impotence
TR200200099T2 (tr) 1999-07-23 2002-06-21 Shionogi &Co., Ltd. Th2 farklılaşma inhibitörleri
SI1224174T1 (en) 1999-10-15 2003-12-31 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
ATE391123T1 (de) 1999-11-15 2008-04-15 Janssen Pharmaceutica Nv Triazole als farnesyl-transferase-hemmer
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
US20030216385A1 (en) 2000-05-19 2003-11-20 Takahiko Tobe Triazole derivatives
MXPA02011373A (es) * 2000-05-19 2003-06-26 Yamanouchi Pharma Co Ltd Derivados de triazol.
AU2002367752A1 (en) 2001-10-03 2003-11-17 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0208579D0 (en) 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
EP1673355A1 (en) * 2003-09-22 2006-06-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
EP1701959A1 (en) 2003-12-22 2006-09-20 Pfizer Limited Triazole derivatives as vasopressin antagonists
WO2005082866A2 (en) * 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
CA2563963A1 (en) 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists

Also Published As

Publication number Publication date
MA29160B1 (fr) 2008-01-02
TW200637847A (en) 2006-11-01
CA2595569C (en) 2010-07-20
AR055303A1 (es) 2007-08-15
JP4124805B1 (ja) 2008-07-23
US10150752B2 (en) 2018-12-11
NL1030961C2 (nl) 2007-01-12
US20090253674A1 (en) 2009-10-08
JP2008528476A (ja) 2008-07-31
EP1841758A1 (en) 2007-10-10
CN101107243A (zh) 2008-01-16
HK1113927A1 (en) 2008-10-17
WO2006077496A1 (en) 2006-07-27
DOP2006000014A (es) 2006-07-31
BRPI0606463A2 (pt) 2009-06-30
US20130137671A1 (en) 2013-05-30
AP2007004047A0 (en) 2007-06-30
US7557131B2 (en) 2009-07-07
KR100936854B1 (ko) 2010-01-14
US20150322042A1 (en) 2015-11-12
DK1841758T3 (da) 2010-01-18
IL184148A0 (en) 2007-10-31
GB0501190D0 (en) 2005-03-02
MX2007008757A (es) 2008-03-10
PE20060875A1 (es) 2006-09-04
ZA200705718B (en) 2008-08-27
EA200701328A1 (ru) 2007-12-28
EP1841758B1 (en) 2009-11-18
AU2006207300B2 (en) 2011-03-03
AU2006207300A1 (en) 2006-07-27
TNSN07275A1 (fr) 2008-12-31
ES2334517T3 (es) 2010-03-11
US9394278B2 (en) 2016-07-19
IL184148A (en) 2013-06-27
CA2595569A1 (en) 2006-07-27
US9023872B2 (en) 2015-05-05
KR20070091023A (ko) 2007-09-06
US20060160786A1 (en) 2006-07-20
US20170114040A1 (en) 2017-04-27
UY29339A1 (es) 2006-08-31
CN101107243B (zh) 2010-11-24
DE602006010508D1 (de) 2009-12-31
GT200600024A (es) 2006-08-23
NO20074177L (no) 2007-10-16
ATE449091T1 (de) 2009-12-15
NO338420B1 (no) 2016-08-15
NL1030961A1 (nl) 2006-07-21
PA8660401A1 (es) 2006-09-08
US8207198B2 (en) 2012-06-26

Similar Documents

Publication Publication Date Title
CR9219A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
ECSP066541A (es) Nuevos derivados de piridazin-3(2h)-ona
UY30748A1 (es) Compuesto0s novedosos
CL2012000059A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras.
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
CR8254A (es) [1,8] naftidrin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
ECSP088925A (es) Nitrilos espirocíclicos como inhibidores de proteasa
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
CR9954A (es) Derivados de pirazina
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
UY28524A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
UY30534A1 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapéutica como antagonistas de los receptores de urotensina ii
WO2005082866A3 (en) Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
TW200745122A (en) New compounds I
GT200500026A (es) Derivados de beta-aminoacidos como inhibidores del factor xa.
BRPI0511979A (pt) derivados de triazóis substituìdos como antagonistas de oxitocina, composição farmacêutica compreendendo os referidos derivados, bem como uso dos mesmos
EA201000703A1 (ru) Производные пиразола в качестве ингибиторов 5-lo
WO2006100588A8 (en) Substituted triazole derivatives as oxytocin antagonists
UY28839A1 (es) Agentes terapeuticos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)